Orexin antagonists for neuropsychiatric disease: Progress and potential pitfalls

Frontiers in Neuroscience

Volumn , Issue 8 FEB, 2014, Pages

  Yeoh, Jiann Wei ^a   Campbell, Erin J ^a   James, Morgan H ^a   Graham, Brett A ^a   Dayas, Christopher V ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Anxiety; Cocaine; Depression; Hypothalamus; Orexin; Reinstatement; Reward seeking; Stress

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; ACT 335827; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALMOREXANT; AMPHETAMINE; CHEMICALS AND DRUGS; CORTICOTROPIN; DUAL OREXIN RECEPTOR ANTAGONIST; GSK 1059865; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PROTEIN FOS; SB 410220; SB 649868; SB 674042; SINGLE OREXIN RECEPTOR ANTAGONIST; SUVOREXANT; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 2; VESICULAR INHIBITORY AMINO ACID TRANSPORTER;

AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ANXIETY; BODY TEMPERATURE; CHRONIC STRESS; COCAINE DEPENDENCE; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DEPRESSION; DRUG DEPENDENCE; EARLY LIFE STRESS; FOOTSHOCK; HEART RATE; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IMMOBILIZATION STRESS; IMMUNOREACTIVITY; LATERAL HYPOTHALAMUS; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NEUROPSYCHIATRY; NONHUMAN; REVIEW; REWARD; SYNAPTIC TRANSMISSION; THALAMUS; UPREGULATION;

EID: 84898046033     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00036     Document Type: Review

References (135)

1. Ahmed, S. H., Lutjens, R., van der Stap, L. D., Lekic, D., Romano-Spica, V., Morales, M., et al. (2005). Gene expression evidence for remodeling of lateral hypothalamic circuitry in cocaine addiction. Proc. Natl. Acad. Sci. U.S.A. 102, 11533-11538. doi: 10.1073/pnas.0504438102
2. Allard, J. S., Tizabi, Y., Shaffery, J. P., Trouth, C. O., and Manaye, K. (2004). Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 38, 311-315. doi: 10.1016/j.npep.2004.06.004
3. Ammoun, S., Holmqvist, T., Shariatmadari, R., Oonk, H. B., Detheux, M., Parmentier, M., et al. (2003). Distinct recognition of OX1 and OX2 receptors by orexin peptides. J. Pharmacol. Exp. Ther. 305, 507-514. doi: 10.1124/jpet.102.048025
4. Annerbrink, K., Westberg, L., Olsson, M., Andersch, S., Sjödin, I., Holm, G., et al. (2011). Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr. Genet. 21, 85-89. doi: 10.1097/YPG.0b013e328341a3db
5. Arendt, D. H., Ronan, P. J., Oliver, K. D., Callahan, L. B., Summers, T. R., and Summers, C. H. (2013). Depressive behavior and activation of the orexin/hypocretin system. Behav. Neurosci. 127, 86-94. doi: 10.1037/a0031442
6. Aston-Jones, G., Smith, R. J., Sartor, G. C., Moorman, D. E., Massi, L., Tahsili-Fahadan, P., et al. (2010). Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res. 1314, 74-90. doi: 10.1016/j.brainres.2009.09.106
7. Bergman, J. M., Roecker, A. J., Mercer, S. P., Bednar, R. A., Reiss, D. R., Ransom, R. W., et al. (2008). Proline bis-amides as potent dual orexin receptor antagonists. Bioorg. Med. Chem. Lett. 18, 1425-1430. doi: 10.1016/j.bmcl.2008.01.001
8. Blouin, A. M., Fried, I., Wilson, C. L., Staba, R. J., Behnke, E. J., Lam, H. A., et al. (2013). Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun. 4: 1547. doi: 10.1038/ncomms2461
9. Borgland, S. L., Chang, S. J., Bowers, M. S., Thompson, J. L., Vittoz, N., Floresco, S. B., et al. (2009). Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J. Neurosci. 29, 11215-11225. doi: 10.1523/JNEUROSCI.6096-08.2009
10. Boutrel, B., Cannella, N., and de Lecea, L. (2010). The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res. 1314, 103-111. doi: 10.1016/j.brainres.2009.11.054
11. Boutrel, B., and de Lecea, L. (2008). Addiction and arousal: the hypocretin connection. Physiol. Behav. 93, 947-951. doi: 10.1016/j.physbeh.2007.11.022
12. Boutrel, B., Kenny, P. J., Specio, S. E., Martin-Fardon, R., Markou, A., Koob, G. F., et al. (2005). Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. U.S.A. 102, 19168-19173. doi: 10.1073/pnas.0507480102
13. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155. doi: 10.1038/nm1544
14. Brown, R. M., Khoo, S. Y.-S., and Lawrence, A. J. (2013). Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. Int. J. Neuropsychopharmacol. 16, 2067-2079. doi: 10.1017/S1461145713000333
15. Brundin, L., Bjorkqvist, M., Petersen, A., and Traskman-Bendz, L. (2007a). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 17, 573-579. doi: 10.1016/j.euroneuro.2007.01.005
16. Brundin, L., Bjorkqvist, M., Traskman-Bendz, L., and Petersen, A. (2009). Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J. Affect. Disord. 113, 179-182. doi: 10.1016/j.jad.2008.04.011
17. Brundin, L., Petersen, A., Bjorkqvist, M., and Traskman-Bendz, L. (2007b). Orexin and psychiatric symptoms in suicide attempters. J. Affect. Disord. 100, 259-263. doi: 10.1016/j.jad.2006.10.019
18. Burdakov, D., Gerasimenko, O., and Verkhratsky, A. (2005). Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormones and orexin neurons in situ. J. Neurosci. 25, 2429-2433. doi: 10.1523/JNEUROSCI.4925-04.2005
19. Campbell, E. J., James, M. H., Richardson, H. N., Hodgson, D. M., and Dayas, C. V. (2013). Orexin (Hypocretin) Neurons are Hyporesponsive to Stress in Adulthood Following Maternal Separation: Effects Reversed by Voluntary Exercise in Male but not Female Rats. San Diego, CA: Paper presented at the Society for Neuroscience.
20. Chang, H., Saito, T., Ohiwa, N., Tateoka, M., Deocaris, C. C., Fujikawa, T., et al. (2007). Inhibitory effects of an orexin-2 receptor antagonist on orexin A-and stress-induced ACTH responses in conscious rats. Neurosci. Res. 57, 462-466. doi: 10.1016/j.neures.2006.11.009
21. Charney, D. S., and Manji, H. K. (2004). Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci. STKE 2004, 1-11. doi: 10.1126/stke.2252004re5
22. Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451. doi: 10.1016/S0092-8674(00)81973-X
23. Chen, B. T., Bowers, M. S., Martin, M., Hopf, F. W., Guillory, A. M., Carelli, R. M., et al. (2008). Cocaine but not natural reward self-administration nor passive cocaine infusions produces persistent LTP in VTA. Neuron 59, 288-297. doi: 10.1016/j.neuron.2008.05.024
24. Chen, X., Wang, H., Lin, Z., Li, S., Li, Y., Bergen, H. T., et al. (2013). Orexins (hypocretins) contribute to fear and avoidance in rats exposed to a single episode of footshocks. Brain Struct. Funct. doi: 10.1007/s00429-013-0626-3. [Epub ahead of print].
25. Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., et al. (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320-5332. doi: 10.1021/jm100541c
26. Date, Y., Mondal, M. S., Matsukura, S., Ueta, Y., Yamashita, H., Kaiya, H., et al. (2000). Distribution of orexin/hypocretin in the rat median eminence and pituitary. Brain Res. Mol. Brain Res. 76, 1-6. doi: 10.1016/S0169-328X(99)00317-4
27. Day, T. A., and Walker, F. R. (2007). More appraisal please: a commentary on Pfaff et al. (2007) "Relations between mechanisms of CNS arousal and mechanisms of stress." Stress 10, 311-313. doi: 10.1080/10253890701638204
28. Dayas, C. V., Buller, K. M., Crane, J. W., Xu, Y., and Day, T. A. (2001). Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups. Eur. J. Neurosci. 14, 1143-1152. doi: 10.1046/j.0953-816x.2001.01733.x
29. de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327. doi: 10.1073/pnas.95.1.322
30. Dugovic, C., Shelton, J. E., Aluisio, L. E., Fraser, I. C., Jiang, X., Sutton, S. W., et al. (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142-151. doi: 10.1124/jpet.109.152009
31. Espana, R. A., Oleson, E. B., Locke, J. L., Brookshire, B. R., Roberts, D. C., and Jones, S. R. (2010). The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur. J. Neurosci. 31, 336-348. doi: 10.1111/j.1460-9568.2009.07065.x
32. Feng, P., Vurbic, D., Wu, Z., and Strohl, K. P. (2007). Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res. 1154, 163-172. doi: 10.1016/j.brainres.2007.03.077
33. Furlong, T. M., Vianna, D. M. L., Liu, L., and Carrive, P. (2009). Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur. J. Neurosci. 30, 1603-1614. doi: 10.1111/j.1460-9568.2009.06952.x
34. Gozzi, A., Lepore, S., Vicentini, E., Merlo-Pich, E., and Bifone, A. (2013). Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine. Neuropsychopharmacology 38, 2120-2130. doi: 10.1038/npp.2013.109
35. Gozzi, A., Turrini, G., Piccoli, L., Massagrande, M., Amantini, D., Antolini, M., et al. (2011). Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 6:e16406. doi: 10.1371/journal.pone.0016406
36. Graham, Y. P., Heim, C., Goodman, S. H., Miller, A. H., and Nemeroff, C. B. (1999). The effects of neonatal stress on brain development: implications for psychopathology. Dev. Psychopathol. 11, 545-565. doi: 10.1017/S0954579499002205
37. Grillon, C. (2008). Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology (Berl.) 199, 421-437. doi: 10.1007/s00213-007-1019-1
38. Hamlin, A. S., Clemens, K. J., and McNally, G. P. (2008). Renewal of extinguished cocaine-seeking. Neuroscience 151, 659-670. doi: 10.1016/j.neuroscience.2007.11.018
39. Hamlin, A. S., Newby, J., and McNally, G. P. (2007). The neural correlates and role of D1 dopamine receptors in renewal of extinguished alcohol-seeking. Neuroscience 146, 525-536. doi: 10.1016/j.neuroscience.2007.01.063
40. Harris, G. C., and Aston-Jones, G. (2006). Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 29, 571-577. doi: 10.1016/j.tins.2006.08.002
41. Harris, G. C., Wimmer, M., and Aston-Jones, G. (2005). A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437, 556-559. doi: 10.1038/nature04071
42. Haynes, A. C., Chapman, H., Taylor, C., Moore, G. B., Cawthorne, M. A., Tadayyon, M., et al. (2002). Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul. Pept. 104, 153-159. doi: 10.1016/S0167-0115(01)00358-5
43. Haynes, A. C., Jackson, B., Chapman, H., Tadayyon, M., Johns, A., Porter, R. A., et al. (2000). A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul. Pept. 96, 45-51. doi: 10.1016/S0167-0115(00)00199-3
44. Heydendael, W., Sharma, K., Iyer, V., Luz, S., Piel, D., Beck, S., et al. (2011). Orexins/hypocretins act in the posterior paraventricular thalamic nucleus during repeated stress to regulate facilitation to novel stress. Endocrinology 152, 4738-4752. doi: 10.1210/en.2011-1652
45. Hirose, M., Egashira, S., Goto, Y., Hashihayata, T., Ohtake, N., Iwaasa, H., et al. (2003). N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. 13, 4497-4499. doi: 10.1016/j.bmcl.2003.08.038
46. Hollander, J. A., Lu, Q., Cameron, M. D., Kamenecka, T. M., and Kenny, P. J. (2008). Insular hypocretin transmission regulates nicotine reward. Proc. Natl. Acad. Sci. U.S.A. 105, 19480-19485. doi: 10.1073/pnas.0808023105
47. Hollander, J. A., Pham, D., Fowler, C. D., and Kenny, P. J. (2012). Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front. Behav. Neurosci. 6: 47. doi: 10.3389/fnbeh.2012.00047
48. Horvath, T. L., and Gao, X. B. (2005). Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. Cell Metab. 1, 279-286. doi: 10.1016/j.cmet.2005.03.003
49. Hutcheson, D. M., Quarta, D., Halbout, B., Rigal, A., Valerio, E., and Heidbreder, C. (2011). Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward. Behav. Pharmacol. 22, 173-181. doi: 10.1097/FBP.0b013e328343d761
50. Ida, T., Nakahara, K., Murakami, T., Hanada, R., Nakazato, M., and Murakami, N. (2000). Possible involvement of orexin in the stress reaction in rats. Biochem. Biophys. Res. Commun. 270, 318-323. doi: 10.1006/bbrc.2000.2412
51. Ito, N., Yabe, T., Gamo, Y., Nagai, T., Oikawa, T., Yamada, H., et al. (2008). I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 157, 720-732. doi: 10.1016/j.neuroscience.2008.09.042
52. James, M. H., Charnley, J. L., Levi, E. M., Jones, E., Yeoh, J. W., Smith, D. W., et al. (2011). Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. Int. J. Neuropsychopharmacol. 14, 684-690. doi: 10.1017/S1461145711000423
53. James, M. H., Yeoh, J. W., Graham, B. A., and Dayas, C. V. (2012). Insights for developing pharmacological treatments for psychostimulant relapse targeting hypothalamic peptide systems. Addict. Res. Ther. s4, 1-13. doi: 10.4172/2155-6105.S4-008
54. Jászberényi, M., Bujdosó, E., Pataki, I., and Telegdy, G. (2000). Effects of orexins on the hypothalamic-pituitary-adrenal system. J. Neuroendocrinol. 12, 1174-1178. doi: 10.1046/j.1365-2826.2000.00572.x
55. Jennings, J. H., Rizzi, G., Stamatakis, A. M., Ung, R. L., and Stuber, G. D. (2013). The inhibitory circuit architecture of the lateral hypothalamus orchestrates feeding. Science 341, 1517-1521. doi: 10.1126/science.1241812
56. Johnson, P. L., Samuels, B. C., Fitz, S. D., Federici, L. M., Hammes, N., Early, M. C., et al. (2012). Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Physiol. Behav. 107, 733-742. doi: 10.1016/j.physbeh.2012.04.016
57. Johnson, P. L., Truitt, W., Fitz, S. D., Minick, P. E., Dietrich, A., Sanghani, S., et al. (2010). A key role for orexin in panic anxiety. Nat. Med. 16, 111-115. doi: 10.1038/nm.2075
58. Jupp, B., Krivdic, B., Krstew, E., and Lawrence, A. J. (2011). The orexin(1) receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res. 1391, 54-59. doi: 10.1016/j.brainres.2011.03.045
59. Katz, R. J., Roth, K. A., and Carroll, B. J. (1981). Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci. Biobehav. Rev. 5, 247-251. doi: 10.1016/0149-7634(81)90005-1
60. Kendler, K. S., Karkowski, L. M., and Prescott, C. A. (1999). Causal relationship between stressful life events and the onset of major depression. Am. J. Psychiatry 156, 837-841.
61. Kuru, M., Ueta, Y., Serino, R., Nakazato, M., Yamamoto, Y., Shibuya, I., et al. (2000). Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 11, 1977-1980. doi: 10.1097/00001756-200006260-00034
62. Langmead, C. J., Jerman, J. C., Brough, S. J., Scott, C., Porter, R. A., and Herdon, H. J. (2004). Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. 141, 340-346. doi: 10.1038/sj.bjp.0705610
63. Laorden, M. L., Ferenczi, S., Pinter-Kubler, B., Gonzalez-Martin, L. L., Lasheras, M. C., Kovacs, K. J., et al. (2012). Hypothalamic orexin-a neurons are involved in the response of the brain stress system to morphine withdrawal. PLoS ONE 7: e36871. doi: 10.1371/journal.pone.0036871
64. Lawrence, A. J. (2010). Regulation of alcohol-seeking by orexin (hypocretin) neurons. Brain Res. 1314, 124-129. doi: 10.1016/j.brainres.2009.07.072
65. Lawrence, A. J., Cowen, M. S., Yang, H. J., Chen, F., and Oldfield, B. (2006). The orexin system regulates alcohol-seeking in rats. Br. J. Pharmacol. 148, 752-759. doi: 10.1038/sj.bjp.0706789
66. LeSage, M. G., Perry, J. L., Kotz, C. M., Shelley, D., and Corrigall, W. A. (2010). Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology (Berl.) 209, 203-212. doi: 10.1007/s00213-010-1792-0
67. Li, Y., Gao, X.-B., Sakurai, T., and Van den Pol, A. N. (2002). Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 36, 1169-1181. doi: 10.1016/S0896-6273(02)01132-7
68. Li, Y., Li, S., Wei, C., Wang, H., Sui, N., and Kirouac, G. J. (2010). Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats. Psychopharmacology (Berl.) 212, 251-265. doi: 10.1007/s00213-010-1948-y
69. Lutter, M., Krishnan, V., Russo, S. J., Jung, S., McClung, C. A., and Nestler, E. J. (2008). Orexin signaling mediates the antidepressant-like effect of calorie restriction. J. Neurosci. 28, 3071-3075. doi: 10.1523/JNEUROSCI.5584-07.2008
70. Mahler, S., Smith, R., and Aston-Jones, G. (2013). Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl.) 226, 687-698. doi: 10.1007/s00213-012-2681-5
71. Mahler, S. V., Smith, R. J., Moorman, D. E., Sartor, G. C., and Aston-Jones, G. (2012). Multiple roles for orexin/hypocretin in addiction. Prog. Brain Res. 198, 79-121. doi: 10.1016/B978-0-444-59489-1.00007-0
72. Malherbe, P., Borroni, E., Gobbi, L., Knust, H., Nettekoven, M., Pinard, E., et al. (2009a). Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br. J. Pharmacol. 156, 1326-1341. doi: 10.1111/j.1476-5381.2009.00127.x
73. Malherbe, P., Borroni, E., Pinard, E., Wettstein, J. G., and Knoflach, F. (2009b). Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol. Pharmacol. 76, 618-631. doi: 10.1124/mol.109.055152
74. Marchant, N. J., Millan, E. Z., and McNally, G. P. (2012). The hypothalamus and the neurobiology of drug seeking. Cell. Mol. Life Sci. 69, 581-597. doi: 10.1007/s00018-011-0817-0
75. Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., et al. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25. doi: 10.1002/cne.1190
76. Martin-Fardon, R., and Weiss, F. (2012). N-(2-Methyl-6-benzoxazolyl)-N'-1,5-n aphthyridin-4-yl urea (SB334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: comparison with natural reward seeking. Addict. Biol. doi: 10.1111/j.1369-1600.2012.00480.x. [Epub ahead of print].
77. Martin-Fardon, R., and Weiss, F. (2014). Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking. Neuroreport. doi: 10.1097/WNR.0000000000000120. [Epub ahead of print].
78. Martins, P. J., D'Almeida, V., Pedrazzoli, M., Lin, L., Mignot, E., and Tufik, S. (2004). Increased hypocretin-1 (orexin-a) levels in cerebrospinal fluid of rats after short-term forced activity. Regul. Pept. 117, 155-158. doi: 10.1016/j.regpep.2003.10.003
79. McAtee, L. C., Sutton, S. W., Rudolph, D. A., Li, X., Aluisio, L. E., Phuong, V. K., et al. (2004). Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. 14, 4225-4229. doi: 10.1016/j.bmcl.2004.06.032
80. Mikrouli, E., Wortwein, G., Soylu, R., Mathe, A. A., and Petersen, A. (2011). Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides 45, 401-406. doi: 10.1016/j.npep.2011.07.010
81. Moreno, G., Perelló, M., Gaillard, R., and Spinedi, E. (2005). Orexin a stimulates hypothalamic-pituitary-adrenal (HPA) axis function, but not food intake, in the absence of full hypothalamic NPY-ergic activity. Endocrine 26, 99-106. doi: 10.1385/endo:26:2:099
82. Morshedi, M. M., and Meredith, G. E. (2008). Repeated amphetamine administration induces Fos in prefrontal cortical neurons that project to the lateral hypothalamus but not the nucleus accumbens or basolateral amygdala. Psychopharmacology (Berl.) 197, 179-189. doi: 10.1007/s00213-007-1021-7
83. Nocjar, C., Zhang, J., Feng, P., and Panksepp, J. (2012). The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience 218, 138-153. doi: 10.1016/j.neuroscience.2012.05.033
84. Nollet, M., Gaillard, P., Minier, F., Tanti, A., Belzung, C., and Leman, S. (2011). Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 61, 336-346. doi: 10.1016/j.neuropharm.2011.04.022
85. Nollet, M., Gaillard, P., Tanti, A., Girault, V., Belzung, C., and Leman, S. (2012). Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 37, 2210-2221. doi: 10.1007/s00213-007-1021-7
86. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., et al. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
87. Plaza-Zabala, A., Flores, á., Maldonado, R., and Berrendero, F. (2012). Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. Biol. Psychiatry 71, 214-223. doi: 10.1016/j.biopsych.2011.06.025
88. Plaza-Zabala, A., Flores, A., Martin-Garcia, E., Saravia, R., Maldonado, R., and Berrendero, F. (2013). A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior. Neuropsychopharmacology 38, 1724-1736. doi: 10.1038/npp.2013.72
89. Plaza-Zabala, A., Martin-Garcia, E., de Lecea, L., Maldonado, R., and Berrendero, F. (2010). Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. J. Neurosci. 30, 2300-2310. doi: 10.1523/JNEUROSCI.5724-09.2010
90. Porter, R. A., Chan, W. N., Coulton, S., Johns, A., Hadley, M. S., Widdowson, K., et al. (2001). 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. 11, 1907-1910. doi: 10.1016/S0960-894X(01)00343-2
91. Rainero, I., Ostacoli, L., Rubino, E., Gallone, S., Picci, L. R., Fenoglio, P., et al. (2011). Association between major mood disorders and the hypocretin receptor 1 gene. J. Affect. Disord. 130, 487-491. doi: 10.1016/j.jad.2010.10.033
92. Rao, Y., Mineur, Y. S., Gan, G., Wang, A. H., Liu, Z. W., Wu, X., et al. (2013). Repeated in vivo exposure of cocaine induces long-lasting synaptic plasticity in hypocretin/orexin-producing neurons in the lateral hypothalamus in mice. J. Physiol. 591(Pt 7), 1951-1966. doi: 10.1113/jphysiol.2012.246983
93. Renzulli, C., Nash, M., Wright, M., Thomas, S., Zamuner, S., Pellegatti, M., et al. (2011). Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans. Drug Metab. Dispos. 39, 215-227. doi: 10.1124/dmd.110.035386
94. Richards, J. K., Simms, J. A., Steensland, P., Taha, S. A., Borgland, S. L., Bonci, A., et al. (2008). Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl.) 199, 109-117. doi: 10.1007/s00213-008-1136-5
95. Rodgers, R. J., Wright, F. L., Snow, N. F., and Taylor, L. J. (2013). Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice. Behav. Brain Res. 243, 213-219. doi: 10.1016/j.bbr.2012.12.064
96. Rotter, A., Asemann, R., Decker, A., Kornhuber, J., and Biermann, T. (2011). Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. J. Affect. Disord. 131, 186-192. doi: 10.1016/j.jad.2010.12.004
97. Russell, S. H., Small, C. J., Dakin, C. L., Abbott, C. R., Morgan, D. G., Ghatei, M. A., et al. (2001). The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. J. Neuroendocrinol. 13, 561-566. doi: 10.1046/j.1365-2826.2001.00672.x
98. Russo, S. J., and Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609-625. doi: 10.1038/nrn3381
99. Rusyniak, D. E., Zaretsky, D. V., Zaretskaia, M. V., Durant, P. J., and DiMicco, J. A. (2012). The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress. Physiol. Behav. 107, 743-750. doi: 10.1016/j.physbeh.2012.02.010
100. Sakamoto, F., Yamada, S., and Ueta, Y. (2004). Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. Regul. Pept. 118, 183-191. doi: 10.1016/j.regpep.2003.12.014
101. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585. doi: 10.1016/S0092-8674(00)80949-6
102. Salomon, R. M., Ripley, B., Kennedy, J. S., Johnson, B., Schmidt, D., Zeitzer, J. M., et al. (2003). Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96-104. doi: 10.1016/S0006-3223(02)01740-7
103. Sartor, G. C., and Aston-Jones, G. (2012). A septal-hypothalamic pathway drives orexin neurons, which is necessary for conditioned cocaine preference. J. Neurosci. 32, 4623-4631. doi: 10.1523/JNEUROSCI.4561-11.2012
104. Scammell, T. E., and Winrow, C. J. (2011). Orexin receptors: pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 51, 243-266. doi: 10.1146/annurev-pharmtox-010510-100528
105. Schmidt, F. M., Arendt, E., Steinmetzer, A., Bruegel, M., Kratzsch, J., Strauss, M., et al. (2011). CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 190, 240-243. doi: 10.1016/j.psychres.2011.06.004
106. Schneider, E. R., Rada, P., Darby, R. D., Leibowitz, S. F., and Hoebel, B. G. (2007). Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin. Alcohol. Clin. Exp. Res. 31, 1858-1865. doi: 10.1111/j.1530-0277.2007.00510.x
107. Schöne, C., Venner, A., Knowles, D., Karnani, M. M., and Burdakov, D. (2011). Dichotomous cellular properties of mouse orexin/hypocretin neurons. J. Physiol. 589, 2767-2779. doi: 10.1113/jphysiol.2011.208637
108. Scott, M. M., Marcus, J. N., Pettersen, A., Birnbaum, S. G., Mochizuki, T., Scammell, T. E., et al. (2011). Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav. Brain Res. 222, 289-294. doi: 10.1016/j.bbr.2011.02.044
109. Sears, R. M., Fink, A. E., Wigestrand, M. B., Farb, C. R., de Lecea, L., and LeDoux, J. E. (2013). Orexin/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus. Proc. Natl. Acad. Sci. U.S.A. 110, 20260-20265. doi: 10.1073/pnas.1320325110
110. Sharf, R., Guarnieri, D. J., Taylor, J. R., and DiLeone, R. J. (2010). Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Res. 1317, 24-32. doi: 10.1016/j.brainres.2009.12.035
111. Shoblock, J. R., Welty, N., Aluisio, L., Fraser, I., Motley, S. T., Morton, K., et al. (2010). Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology (Berl.) 215, 191-203. doi: 10.1007/s00213-010-2127-x
112. Smart, D., Sabido-David, C., Brough, S. J., Jewitt, F., Johns, A., Porter, R. A., et al. (2001). SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 132, 1179-1182. doi: 10.1038/sj.bjp.0703953
113. Smith, R. J., and Aston-Jones, G. (2012). Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur. J. Neurosci. 35, 798-804. doi: 10.1111/j.1460-9568.2012.08013.x
114. Smith, R. J., See, R. E., and Aston-Jones, G. (2009). Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur. J. Neurosci. 30, 493-503. doi: 10.1111/j.1460-9568.2009.06844.x
115. Smith, R. J., Tahsili-Fahadan, P., and Aston-Jones, G. (2010). Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology 58, 179-184. doi: 10.1016/j.neuropharm.2009.06.042
116. Soya, S., Shoji, H., Hasegawa, E., Hondo, M., Miyakawa, T., Yanagisawa, M., et al. (2013). Orexin receptor-1 in the locus coeruleus plays an important role in cue-dependent fear memory consolidation. J. Neurosci. 33, 14549-14557. doi: 10.1523/JNEUROSCI.1130-13.2013
117. Srinivasan, S., Simms, J. A., Nielsen, C. K., Lieske, S. P., Bito-Onon, J. J., Yi, H., et al. (2012). The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. PLoS ONE 7: e44726. doi: 10.1371/journal.pone.0044726
118. Staples, L. G., and Cornish, J. L. (2014). The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: An investigation of Trial 1 and Trial 2 effects. Horm. Behav. doi: 10.1016/j.yhbeh.2013.12.014. [Epub ahead of print].
119. Steiner, M. A., Gatfield, J., Brisbare-Roch, C., Dietrich, H., Treiber, A., Jenck, F., et al. (2013a). Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8, 898-903. doi: 10.1002/cmdc.201300003
120. Steiner, M. A., Lecourt, H., and Jenck, F. (2012). The brain orexin system and almorexant in fear-conditioned startle reactions in the rat. Psychopharmacology 223, 465-475. doi: 10.1007/s00213-012-2736-7
121. Steiner, M. A., Lecourt, H., and Jenck, F. (2013c). The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. Int. J. Neuropsychopharmacol. 16, 417-432. doi: 10.1017/S1461145712000193
122. Steiner, M. A., Sciarretta, C., Brisbare-Roch, C., Strasser, D. S., Studer, R., and Jenck, F. (2013b). Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology 38, 560-571. doi: 10.1016/j.psyneuen.2012.07.016
123. Strawn, J. R., Pyne-Geithman, G. J., Ekhator, N. N., Horn, P. S., Uhde, T. W., Shutter, L. A., et al. (2010). Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology 35, 1001-1007. doi: 10.1016/j.psyneuen.2010.01.001
124. Sutcliffe, J. G., and de Lecea, L. (2002). The hypocretins: setting the arousal threshold. Nat. Rev. Neurosci. 3, 339-349. doi: 10.1038/nrn808
125. Suzuki, M., Beuckmann, C. T., Shikata, K., Ogura, H., and Sawai, T. (2005). Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res. 1044, 116-121. doi: 10.1016/j.brainres.2005.03.002
126. Taheri, S., Gardiner, J., Hafizi, S., Murphy, K., Dakin, C., Seal, L., et al. (2001). Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats. Neuroreport 12, 459-464. doi: 10.1097/00001756-200103050-00008
127. Taheri, S., Zeitzer, J. M., and Mignot, E. (2002). The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu. Rev. Neurosci. 25, 283-313. doi: 10.1146/annurev.neuro.25.112701.142826
128. Trivedi, P., Yu, H., MacNeil, D. J., Van der Ploeg, L. H., and Guan, X. M. (1998). Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 438, 71-75. doi: 10.1016/S0014-5793(98)01266-6
129. Ulrich-Lai, Y. M., and Herman, J. P. (2009). Neural regulation of endocrine and autonimic stress responses. Nat. Rev. Neurosci. 10, 397-409. doi: 10.1038/nrn2647
130. von der Goltz, C., Koopmann, A., Dinter, C., Richter, A., Grosshans, M., Fink, T., et al. (2011). Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. Horm. Behav. 60, 644-650. doi: 10.1016/j.yhbeh.2011.08.017
131. Whitman, D. B., Cox, C. D., Breslin, M. J., Brashear, K. M., Schreier, J. D., Bogusky, M. J., et al. (2009). Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 4, 1069-1074. doi: 10.1002/cmdc.200900069
132. Yeoh, J. W., James, M. H., Jobling, P., Bains, J. S., Graham, B. A., and Dayas, C. V. (2012). Cocaine potentiates excitatory drive in the perifornical/lateral hypothalamus. J. Physiol. 590(Pt 16), 3677-3689. doi: 10.1113/jphysiol.2012.230268
133. Zhou, L., Smith, R. J., Do, P. H., Aston-Jones, G., and See, R. E. (2012). Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology 63, 1201-1207. doi: 10.1016/j.neuropharm.2012.07.044
134. Zhou, L., Sun, W. L., and See, R. E. (2011). Orexin receptor targets for anti-relapse medication development in drug addiction. Pharmaceuticals (Basel) 4, 804-821. doi: 10.3390/ph4060804
135. Zhou, Y., Bendor, J., Hofmann, L., Randesi, M., Ho, A., and Kreek, M. J. (2006). Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J. Endocrinol. 191, 137-145. doi: 10.1677/joe.1.06960